Activity of VERU-111, an novel oral α and β tubulin inhibitor, against paclitaxel sensitive and resistant prostate cancer. This is an ASCO Meeting Abstract from the 2018 Genitourinary Cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback